Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab rechallenge versus anti-EGFR-free third-line treatment in RAS wild-type metastatic colorectal cancer
2014-003787-21Phase 3Completed
- Sponsor
- LMU Klinikum
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by LMU Klinikum. Primary endpoint: Overall survival from randomization to third-line treatment. Started Dec 2014; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2014-003787-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003787-21.